Molecular and clinical profiling
$551,509ZIAFY2010CANIH
Division Of Basic Sciences - Nci
Investigators
Linked publications & trials
Paper 22571216Paper 22369320Paper 22341718Paper 22310913Paper 22300426Paper 22271445Paper 22150057Paper 21962239Paper 21942285Paper 21926963Paper 21888256Paper 21836076Paper 21799510Paper 21795746Paper 21745013Paper 21674575Paper 21544856Paper 21261502Paper 21232660Paper 21232659Paper 21232658Paper 21232657Paper 21232655Paper 21232652Paper 20038719Paper 20010166Paper 19608666Paper 19587704Paper 19586941Paper 19582882Paper 19362963Paper 19264919Paper 19213679Paper 19182202Paper 19179464Paper 19016727
Abstract
If we will provide a better understadning of underlying mechanisms of myelomagenesis, then we will be able to reach are goals to (1) define high-risk precursor disease patinets, and to (2) delay and prevent development of multiple myeloma. For example, in 2010, we have developed the first treatment study for smoldering myeloma in the world, using a novel treatment approach;we are planning on using a new modality (a monoclonal antibody which targets natural killer cells, which in turn will cause anti-myeloma effect). If we will be able to reach our goals that will have a major impact on the clinical management and outcome of multiple myeloma in the future.
View original record on NIH RePORTER →